Cusatuzumab (CD70/TNFSF7) Antibody, Monoclonal | 10-877

Cusatuzumab (CD70/TNFSF7) Antibody, Monoclonal | 10-877 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / CD70/TNFSF7 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-lambda

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: ARGX-110

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Cusatuzumab is SIMPLE antibody targeting CD70, which is an immune checkpoint target involving hematological malignancies, various solid tumors, and various autoimmune diseases. cusatuzumab aims to block CD70 by killing CD70-expressing cancer cells through complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis and enhancing antibody-dependent cell-mediated cytotoxicity Immunological monitoring of solid tumors.